An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics
Authors:
- 24 December 2008
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 35 (6) , 619-633
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapyCancer Chemotherapy and Pharmacology, 2005
- Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapyCancer Chemotherapy and Pharmacology, 2005
- Pharmacokinetic/Pharmacodynamic Modelling in Oncological Drug DevelopmentBasic & Clinical Pharmacology & Toxicology, 2005
- Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedbackJournal of Clinical Pharmacy and Therapeutics, 2003
- Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy–Toxicity Mathematical ModelComputers and Biomedical Research, 2000
- Etoposide dosage and pharmacodynamicsCancer Chemotherapy and Pharmacology, 1994
- Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptionsCancer Chemotherapy and Pharmacology, 1993
- A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurementCancer Chemotherapy and Pharmacology, 1991
- Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug DevelopmentJNCI: Journal of the National Cancer Institute, 1990